ʻO ka maʻi diabetes mellitus type 2 he maʻi metabola e kūleʻa ana ma ke ʻano o ka hopena o ke ʻano o ka insulin me nā pū.
ʻAʻole hiki i nā poʻe me kēia ʻano manuise ke mālama i nā pae gula kūpono ma o kaʻai ʻana a me nā kaʻina kūikawā. Kuhi aku nā kauka iā Vildagliptin, e hoʻohaʻahaʻa ana a mālama i ka glucose i loko o nā palena i manaʻo ʻia.
ʻO ka ʻike nui, ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu
He Vindagliptin kahi hnwai o kahi papa hou o nā lāʻau lapaʻau e hoʻohana ikaika ʻia nei i ka mālama ʻana i ka maʻi type 2. Hoʻokomo ia i nā mokika pancreatic a pale i ka hana o ka dipeptidyl peptidase-4. Loaʻa i kahi hopena hypoglycemic.
Hiki ke kuhikuhi ʻia ka lāʻau lapaʻau ma ke ʻano he koʻikoʻi koʻikoʻi, a hui pū me nā lāʻau ʻē aʻe. Hoʻohui pū ʻia me nā derivatives sulfonylurea, me thiazolidinedione, me nā metformin a me nā insulin.
ʻO Vildagliptin ka inoa honua no ka mea kanu ikaika. Hoʻokomo ʻia nā lāʻau ʻelua me kēia mea kanu ma ka mākeke pharmacological, ʻo kā lākou inoa kālepa ʻo Vildagliptin a me Galvus. ʻO ka mea mua aia wale nō ʻo Vildagliptin, ka lua - ka hui pū ʻana o Vildagliptin a me Metformin.
E hoʻokuʻu i nā palapala: nā papa me ke kumu lāʻau o 50 mg, pākuhi - 28 mau ʻāpana.
Pharmacodynamics a me ka pharmacokinetics
ʻO Vildagliptin kahi mea e hoʻowalewale mau i ka peptidase dipeptidyl me ka hoʻonui nui ʻana ma GLP a me HIP. Hoʻokomo ʻia nā Hormones i loko o nā pahu i loko o 24 mau hola a hoʻonui i ke pane ʻana i ka ʻai o ka meaʻai. Hoʻonui ka mea nui i ka ʻike ʻana i nā ʻoi betta no ka glucose. Mālama kēia i ka normalization o ka hana o ke kuhi glucose-hilinaʻi o ka insulin.
Me ka hoʻonui ʻana o ka GLP, nui ka piʻi ʻana i ka ʻike ʻana o nā pūpū alpha i ke kō, e hōʻoia ai i ka maʻamau o ka hoʻoponopono o ka glucose e hilinaʻi nei i ka insulin. Ua hāʻule ka nui o nā lipids i ke koko i ka wā o ka therapy. Me ka hoʻohaʻahaʻa ʻana i ka glucagon, e loaʻa ana kahi emi ʻana i ka pale ʻana i ka insulin.
Hoʻopili koke ka mea hana ikaika, hoʻonui i ke kiʻekiʻe o nā hormones i loko o ke koko ma hope o nā hola 2. Ua hoʻomaopopo ʻia kahi kaukaʻi liʻiliʻi haʻahaʻa - ʻaʻole iʻoi aku ma mua o 10%. Hoʻohālikelike ʻia ʻo Vildagliptin ma waena o nā ʻāpana koko ʻulaʻula a me ka plasma. Loaʻa ka hopena kiʻekiʻe ma hope o 6 mau hola. ʻOi aku ka maikaʻi o ka lāʻau ma luna o ka ʻōpū ʻole, me ka meaʻai, hoʻemi ka hopena o ka hoʻouka ʻana ma kahi liʻiliʻi - ma 19%.
ʻAʻole ia i ka hana a ke hoʻololo i ka isoenzymes, ʻaʻole ia he substrate. Loaʻa ia ma ka koko koko ma hope o nā hola 2. ʻO ka hapalua o ke ola mai 3 mau hola, ʻoiai me ka dosage. ʻO Biotransformation ke ala nui o ka excretion. 15% o ka lāʻau lapaʻau i hōʻike ʻia i loko o nā mea maʻi, 85% - e nā keiki (ʻaʻole i loli ʻo 22.9%). Loaʻa ka hoʻokele kiʻekiʻe loa o ka waiwai i hope o 120 mau minuke.
Nā hōʻailona a me nā contraindications
ʻO ka hōʻike nui no ka hoʻokohu ʻo ka maʻi diabetes type 2. Ua ʻōmaka ʻia ʻo Vildagliptin e like me ke ʻano nui o ka lāʻau, ʻelua mau mea i hoʻohui ʻia (me ka komo ʻana o kekahi lāʻau lapaʻau hou), ʻāpana ʻekolu hui (me ke komo ʻana o nā lāʻau ʻelua).
I ka hihia mua, lawe ʻia ka mālama ʻana me nā hana kino a me kahi meaʻai i wae ʻia maʻa pono ʻia. Inā he mea ʻole ka monotherapy, a hoʻohana ʻia kahi mea paʻakikī me ka hui pū ʻana o nā lāʻau lapaʻau aʻe: nā huahelu sulfonylurea, thiazolidinedione, metformin, insulin.
I waena o nā contraindications:
- keʻaʻaleʻa kūloko;
- hana ʻole;
- hapai
- nā kaha lactase;
- hana aho pili ole;
- nā kānaka ma lalo o 18 mau makahiki;
- hana ʻole naʻau;
- lactation wā;
- galolole galactose.
Nā ʻōkuhi no ka hoʻohana
Lawe ʻia nā papa papaʻa ʻole me ka ʻole e pili ana i ka hoʻokomo ʻana i ka meaʻai. Hoʻoholo ʻia ka noho ʻai e ka kauka, me ka noʻonoʻo ʻana i ke ʻano o ka mea maʻi a me ke ahonui i ka lāʻau lapaʻau.
ʻO ka paena i ʻōlelo ʻia ai ʻo 50-100 mg. Ma kahi maʻi maʻamau 2 make, kauoha ʻia ka lāʻau lapaʻau ma 100 mg i kēlā me kēia lā. I ka hui pū me nā lāʻau lapaʻau ʻē aʻe (ma ka hihia o ka lāʻau ʻelua mau mea), ʻo ka intake i kēlā me kēia lā he 50 mg (1 papa). Me ka loaʻa ʻole o ka hopena i ka wā e mālama ai i ka paʻakikī, hoʻonui ka nui i ka 100 mg.
ʻAʻohe ʻike pololei o ka hoʻohana ʻana i ka lāʻau ma ka wā hāpai a me ka lactation. No laila, pono ka lawe ʻana i kēia māhele i ka lāʻau lapaʻau i hōʻike ʻia. Me ka makaʻala nui e lawe i nā maʻi āpau me nā maʻi puʻupuʻu / keiki.
ʻAʻole aʻo ʻia nā poʻe o lalo o ka 18 mau makahiki e hoʻohana i ka lāʻau lapaʻau. ʻAʻole kūpono ke alakaʻi i nā kaʻa a lawe i ka lāʻau lapaʻau.
Me ka hoʻohana ʻana o vildagliptin, e nānā pono ʻia ka nui o nā leʻe. I ka wā e mālama lōʻihi ai, e ʻōlelo ʻia e lawe i ka nānā ʻana biochemical e nānā i ke kūlana a hiki i ka hoʻoponopono hoʻoponopono ʻia.
Me ka hoʻonui ʻana o nā aminotransferases, pono ia e hoʻāʻo hou i ke koko. Inā hoʻonuiʻia nā hōʻailona ma o ka 3 mau manawa, ua pau ka lāʻau lapaʻau.
Nā hopena ʻaoʻao a me ka overdose
Ma waena o nā hanana hikiʻole ke nānā ʻia:
- asenaiia;
- ulu, hoʻowahāwahā, nawaliwali, ʻeha;
- nausea, puaʻa, hōʻikeʻike i ka esophagitis reflux, flatulence;
- peripheral edema;
- lōkohu
- ʻo ka waiwai kaumaha;
- hepatitis;
- pruritus, urticaria;
- nā ʻano maʻi ʻē aʻe.
Hoʻomaʻamaʻa maikaʻi ka lāʻau lapaʻau e nā mea maʻi, ʻo ka ʻikekema i kēlā me kēia lā a hiki i ka 200 mg i ka lā. Ke hoʻohana nei ma mua o 400 ml, hiki i hope ke ʻano: ka mahana, ke kuehue, ka ʻāʻī ʻana o nā ʻōwili, kuʻuwā, nāwaliwali. Inā hele mai nā hōʻailona, pono e holoi i ka ʻōpū a ʻimi i ke kōkua olakino.
Hiki nō iā ia ke hoʻonui i ka protein C-reactive, myoglobin, creatine phosphokinase. ʻIke pinepine ka Angioedema i ka wā i hui pū ʻia me nā inhibce ACE. Me ka hoʻihoʻi ʻana o ka lāʻau lapaʻau, nalo nā hopena ʻaoʻao.
Nā Kūleʻa Kūʻai a me nā Analog
He haʻahaʻa ka hiki ʻana o ke vildagliptin me nā lāʻau lapaʻau ʻē aʻe. ʻAʻohe hopena i nā lāʻau lapaʻau e hoʻohana pinepine ʻia i ka mālama ʻana i nā maʻi maʻi type like 2 (Metformin, Pioglitazone a me nā mea hou aku) a me nā lāʻau ʻopiʻiki ākea (Amlodipine, Simvastatin).
Hiki i ka lāʻau lapaʻau ke loaʻa kahi inoa kālepa a ʻo ka inoa like paha me ka mea ikaika. I loko o nā lāʻauʻai hiki ke ʻike iā Vildagliptin, Galvus. I ka pilina me nā contraindications, ke kauka nei ke kauka i nā lāʻau like like e hōʻike ana i ka hopena a me ka hopena therapeutic.
Nā ʻano o nā ʻano o ka lāʻau lapaʻau me:
- Onglisa (aktif ingxagliptin);
- Januvia (waiwai - sitagliptin);
- Trazenta (māhele - linagliptin).
ʻO ke kumukūʻai o Vildagliptin e pili ana i 760 a 880 mau rubles, e pili ana i ka palena o ka lāʻau lapaʻau.
Pono ka lāʻau lapaʻau ma ke ana o ka liʻiliʻi loa 25 mau kekelē ma kahi wahi maloʻo.
Nā koho o nā poʻe akamai a me nā maʻi
Loaʻa nā manaʻo o nā poʻe loea a me nā loiloi e pili ana i ka lāʻau lapaʻau.
E kūʻē i ke ʻano o ka lawe ʻana i ka lāʻau lapaʻau i nā mea maʻi me ka maʻi diabetes type 2, ua hōʻike ʻia kēia hopena aʻe.
- ke komo wikiwiki ʻana i ka glucose;
- hoʻoponopono ʻana i kahi hōʻailona kuhikuhi;
- mālie o ka hoʻohana;
- ke kau ʻana o ke kino kino i ka wā o ka monotherapy;
- hui pū ʻia me ka hopena antihypertensive;
- nā hopena hopena i nā hanana loaʻa pinepine;
- nele i nā kūlana hypoglycemic aʻo ke lawe ʻana i ka lāʻau;
- hana maʻamau o ka lipid metabolism;
- pae kiʻekiʻe o ka palekana;
- hōʻano maikaʻi o ka hoʻoliʻi hana;
- kūpono no nā mea maʻi he nui ke ʻano maʻi diabetes type 2.
ʻO Vildagliptin i ka papa noiʻi ua hōʻoia i ka pono a me ka maikaʻi maikaʻi ke kamaʻilio ʻana. Wahi a ke kiʻi loea maʻi a me nā hōʻike kuhikuhi, ʻaʻohe mau mea o ka hypoglycemia i nānā ʻia i ka wā o ka lāʻau lapaʻau.
Manaʻo ʻia ʻo Vildagliptin i kahi lāʻau lapaʻau hypoglycemic pono, i kuhikuhi ʻia no nā maʻi maʻi 2. Hoʻokomo ʻia i ka rehina lāʻau lapaʻau (RLS). Ua hoʻohālikelike ʻia e like me monotherapy a me ka hui pū me nā lawena ʻē aʻe. Aia i ka papa o ka maʻi, ka hopena o ka mālama ʻana, hiki ke hoʻohui ʻia i ka lāʻau me Metmorphine, a me nā derivatives o ka sulfonylurea. E kau ka kauka kauka hele i ke ana kūpono a nānā i ke ʻano o ka mea maʻi. I nā maʻi pinepine me ka maʻi maʻamau maʻi 2 ua loaʻa nā maʻi maʻi. Hoʻopau nui kēia i ka koho o ka holomua haʻahaʻa glucose-hoʻohaʻahaʻa. I kēlā mau kūlana, ʻo ka insulin ka mea maoli kūlohelohe o ka hoʻohaʻahaʻa i nā pae gula. ʻO kona komoʻana nui hiki i ka hypoglycemia ke loaʻa, kaupaona momona. Ma hope o ke aʻo ʻana, ua ʻike ʻia ʻo ka hoʻohana ʻana o Vildagliptin me ka insulin e hiki ai i ka hopena maikaʻi. Hiki ke hoʻonui ʻia ka pilikia o ka hoʻomohala ʻana i nā maʻi cardiovascular, he hōʻemi ʻia ka hypoglycemia, lipid a me ka ʻaila kālaiʻai me ka loaʻa ʻole o ka paona.
Frolova N. M., endocrinologist, kauka o ka helu kiʻekiʻe
ʻO wau ke lawe i ka Vildagliptin no hoʻokahi makahiki hoʻokahi makahiki, ua kuhikuhi ʻia iaʻu e kekahi kauka i hui pū me Metformin. Kaumaha loa au i ka wā o ka mālama lōʻihi e loaʻa iaʻu ke kaumaha. Akā ua ola ʻo ia ma ka 5 kg wale nō i koʻu 85. Ma waena o nā hopena ʻaoʻao, loaʻa iaʻu kahi constipation a me ka nausea. Ma keʻano holoʻokoʻa, hāʻawi ka hopena i ka hopena i makemake ʻia a hala ʻole me nā hopena kūpono ʻole.
Olga, 44 makahiki, Saratov
Nā kumuhana wikiō mai Kauka Malysheva e pili ana i nā huahana hiki ke hoʻohana ʻia e like me ke hoʻohui ʻana i nā lāʻau lapaʻau no ka maʻi maʻi:
ʻO Vildagliptin kahi lāʻau lapaʻau maikaʻi e hoʻohaʻahaʻa i nā pae glucose a hoʻomaikaʻi i ka hana pancreatic. E kōkua nō ia i nā poʻe maʻi hiki ʻole i hiki ke hoʻololi i nā pae kōpaʻa ma o nā hoʻomaʻamaʻa kūikawā a me nā kaha kai.
